Immunol Lett. 2011 Jun 30;137(1-2):78-81. doi: 10.1016/j.imlet.2011.02.021. Epub 2011 Mar 4.
Multipotent adult progenitor cells (MAPC) are clinically being explored as an alternative to mesenchymal stem cells (MSC) for the immunomodulatory control of graft-versus-host disease (GvHD). Here, we performed an explorative study of the immunomodulatory potential of mouse MAPC (mMAPC), in comparison with that of MSC (mMSC) using experimental models of T-cell alloreactivity. Suppressive effects of Oct4-expressing mMAPC have been described previously; here, we studied mMAPC expressing low to no Oct4 ('mClone-3'), recently shown to be most representative for the human MAPC counterpart. mClone-3 and mMSC exhibited similar immunophenotype and in vitro immunogenic behavior. Allogeneic T-cell↔dendritic cell-proliferation assays showed strong dose-dependent T-cell-suppressive effects of both mClone-3 and mMSC. In a popliteal lymph node assay, mClone-3 and mMSC equally suppressed in vivo alloreactive T-cell expansion. We conclude that mouse MAPC and MSC exhibit similar immunosuppressive behavior in in vitro and local in vivo GvHD assays.
多能成体祖细胞（MAPC）正被临床探索作为间充质干细胞（MSC）的替代品，用于控制移植物抗宿主病（GvHD）的免疫调节。在这里，我们使用 T 细胞同种异体反应的实验模型，对鼠 MAPC（mMAPC）的免疫调节潜力进行了探索性研究，与 MSC（mMSC）进行了比较。先前已经描述了表达 Oct4 的 mMAPC 的抑制作用；在这里，我们研究了表达低水平或无 Oct4 的 mMAPC（'mClone-3'），最近证明它最能代表人类 MAPC 的对应物。mClone-3 和 mMSC 表现出相似的免疫表型和体外免疫原性行为。同种异体 T 细胞↔树突状细胞增殖测定显示，mClone-3 和 mMSC 均表现出强烈的、剂量依赖性的 T 细胞抑制作用。在腘淋巴结测定中，mClone-3 和 mMSC 同样抑制体内同种反应性 T 细胞的扩增。我们得出结论，鼠 MAPC 和 MSC 在体外和局部体内 GvHD 测定中表现出相似的免疫抑制行为。
